Drug Trial Radar · NCT03713905
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
293
Actual
Start
Jul 1, 2017
Primary completion
Feb 28, 2022
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- Guangzhou Gloria Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.
Conditions
- Advanced Solid Tumors
Interventions
GLS-010Drug
Recombinant Human Anti-PD-1 Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT)Time frame: 28 days after patient enrolled
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.